Medicus Pharma (MDCX) Non-Current Assets (2024 - 2025)
Medicus Pharma (MDCX) reported Non-Current Assets of $170733.0 for Q4 2025, down 36.43% on a YoY basis from $268571.0 in Q4 2024, and down 13.0% quarter-over-quarter from $196249.0 in Q3 2025.
Medicus Pharma (MDCX) Non-Current Assets (2024 - 2025) Analysis & Trends
Medicus Pharma has reported Non-Current Assets for 2 years, with the latest figure at $170733.0 in Q4 2025.
- For the quarter ending Q4 2025, Non-Current Assets fell 36.43% year-over-year to $170733.0; the trailing twelve-month figure through Dec 2025 stood at $1.9 million (changed N/A YoY), and the FY2025 full-year result was $170733.0, down 36.43% from the prior year.
- Non-Current Assets for Q4 2025 stood at $170733.0, down from $196249.0 in the prior quarter.
- The five-year high for Non-Current Assets was $937897.0 in Q2 2025, with the low at $170733.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 60.81 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 61.74 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 141.72 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 102.93 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 125.00 Mn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 61.03 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 37.64 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 165.18 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 59.27 Bn |
| 10 | Medicus Pharma | 6.05 Mn | 6.15 Mn | - | 170,733.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 170,733.00 |
| Sep 30, 2025 | 196,249.00 |
| Jun 30, 2025 | 937,897.00 |
| Mar 31, 2025 | 570,091.00 |
| Dec 31, 2024 | 268,571.00 |